Analyzing Opko Health


Opko Health and Astrazeneca PLC are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability. Opko Health presently has a consensus price target of $16.43, suggesting a potential upside of 168.00%.



from Biotech News